For Doctors

What is Non-Invasive Prenatal Testing?

Non-Invasive Prenatal Testing (NIPT) is a new DNA-based blood test that measures the risk of trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome) with greater accuracy than traditional first trimester screening.

NIPT requires a single blood draw which poses no threat to the fetus, and can be done as early as 10 weeks gestation.

Please note: We have limited the information provided in the public domain to ensure that we comply with TGA requirements.

Doctors are encouraged to contact us to obtain the password.

How Does NIPT Work?

NIPT helps healthcare professionals give expectant parents accurate information about the most common fetal aneuploidies. By delivering clear information about trisomies earlier in pregnancy, NIPT may minimize anxiety and follow-up invasive procedures due to false-positive results.

NIPT involves testing millions of short fragments of DNA in maternal plasma. Some of these fragments will have come from the placenta, and most will be from the mother.


The number of fragments derived from each chromosome is determined by the Harmony test. In a mother with a chromosomally normal fetus, the proportion of fragments from each chromosome will be within a narrow normal range. But if the fetus has an abnormal number of chromosomes, the fetal contribution for that chromosome will be abnormal and will distort the overall proportion.

A number of different methods have been developed for NIPT, and others are under development. Sonic Genetics regularly reviews the various implementations of NIPT and assesses their performance, scope and cost. Sonic Genetics recommends the Harmony™ prenatal test for NIPT.

What does NIPT screen for?

NIPT screens for Down syndrome (trisomy 21), Edwards syndrome (trisomy 18) and Patau syndrome (trisomy 13). These are the most common autosomal trisomies. They cause moderate to profound intellectual disability and are associated with major congenital malformations.

Sex chromosome abnormalities, such as Turner syndrome (45,X) and Klinefelter syndrome (47,XXY), can also be detected, but with reduced accuracy. Sex chromosome abnormalities are often clinically milder than other chromosomal abnormalities. Testing for sex chromosome abnormalities will also reveal the fetal gender.

It is important to note that chromosomal abnormalities vary widely in the severity of the problems they cause. Some methods can detect trisomies of other chromosomes; however, these trisomies almost always result in spontaneous miscarriage. NIPT is also being extended to detect rare, small deletions in specific areas of certain chromosomes (microdeletions); these more recent developments also have reduced accuracy.

How accurate is NIPT?

NIPT is highly accurate, detecting more than 99% of fetuses with Trisomy 21, and more than 95% of fetuses with Trisomy 18, Trisomy 13 or abnormalities of sex chromosomes. These are much better detection rates than we observe with conventional first trimester screening for these trisomies (85% for trisomy 21, 50% for trisomy 18, and 50% for trisomy 13). NIPT is also much better at identifying fetuses with normal chromosomes than conventional first trimester screening; more than 99.9% of normal fetuses are categorised correctly by NIPT, versus 95% by conventional first trimester screening.

NIPT is a very good screening test, but it is not a diagnostic test. There will occasionally be a difference between the result of the test and the actual chromosomal status of the fetus. This is usually due to the fetus and placenta having different numbers of chromosomes. Such differences can also be due to the mother having an underlying chromosomal abnormality. It is rare for such differences to be due to technical failure of the test.

What is NOT included in NIPT?

NIPT does not detect every genetic abnormality in the fetus, or every developmental problem that might occur during pregnancy.

NIPT will not detect the following conditions:

  1. Less common or ‘atypical’ chromosomal abnormalities. These make up approximately 20% of all chromosomal abnormalities, and occur more commonly in pregnancies with fetal malformations and/or with very high risk scores on combined first trimester screening. These abnormalities can often be detected by invasive genetic testing, i.e. CVS or amniocentesis.
  2. A specific mutation that might be known to run in the family, e.g. cystic fibrosis or Huntington disease. Please contact us on 1800 010 447 if you are concerned about this possibility.
  3. Non-chromosomal disorders, such as neural tube defects, placental abnormalities and intra-uterine growth retardation.

This list of exclusions is not complete.

NIPT does not screen for all chromosomal abnormalities. It does not screen for other genetic disorders or birth defects.

Before using NIPT

NIPT is a new and powerful investigation that carries major clinical implications for mother and fetus. Before proceeding with the test, it is vital that

  • clinicians understand the purpose, performance and limitations of the test
  • patients are informed about these aspects of the investigation, and
  • appropriate consent is provided before the test is initiated.

Sonic Genetics requires that patients provide written consent for this test to assure the clinician and patient that these issues are understood.